---
figid: PMC4653019__oncotarget-06-20474-g006
figtitle: Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor
  signaling and prostate cancer progression
organisms:
- NA
pmcid: PMC4653019
filename: oncotarget-06-20474-g006.jpg
figlink: /pmc/articles/PMC4653019/figure/F6/
number: F6
caption: . A diagram describes the mechanisms by which catalytic Topo II inhibitors
  and anti-AR agents block AR pathway in prostate cancer cells.
papertitle: Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor
  signaling and prostate cancer progression.
reftext: Haolong Li, et al. Oncotarget. 2015 Aug 21;6(24):20474-20484.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9676284
figid_alias: PMC4653019__F6
figtype: Figure
organisms_ner:
- NA
redirect_from: /figures/PMC4653019__F6
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4653019__oncotarget-06-20474-g006.html
  '@type': Dataset
  description: . A diagram describes the mechanisms by which catalytic Topo II inhibitors
    and anti-AR agents block AR pathway in prostate cancer cells.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Abiraterone
  - Enzalutamide
  - Androgen
---
